Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company CombinatoRx has begun dosing of patients in a Phase IIa clinical trial in psoriasis with CRx-191, its topical synergistic combination drug candidate.
Subscribe to our email newsletter
This clinical trial is a 12-day, single-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of CRx-191 in reducing psoriatic infiltrate band thickness in subjects with plaque psoriasis. Approximately 20 subjects with chronic, stable plaque psoriasis in an area sufficient for six treatment fields within an occlusive dressing will be enrolled.
All subjects will receive all treatments in the selected treatment area: CRx-191 low dose, CRx-191 high dose, placebo). Endpoints include reduction from baseline in psoriatic infiltrate as measured by ultrasound at day 12 and will compare between both doses of CRx-191 and its individual components.
Daniel Grau, COO of CombinatoRx, said: “CRx-191 is the first in a family of novel topical product candidates that CombinatoRx is developing. CRx-191 is designed to selectively boost glucocorticosteroid efficacy without enhancing side effects. As such, CRx-191 may represent a new treatment option for dermatologists seeking agents with novel mechanisms to replace traditional topical therapies.”